Trial Profile
The Exploratory Study of Conversion Surgery for Apatinib in Combination With Oxaliplatin/S-1(SOX) for Patients With Unresectable Gastric Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2019
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary) ; Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 31 May 2019 Status changed from recruiting to completed.
- 31 May 2019 Results assessing feasibility of SOX regimen in combination with apatinib in advanced gastric cancer patients, published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 20 Jan 2018 First patients were enrolled in Dec 2016 and Data analysis is planned in Nov 2018, according to the trial design presented at the 2018 Gastrointestinal Cancers Symposium